Article History
Received: 6 June 2021
Accepted: 14 October 2022
First Online: 1 November 2022
Declarations
:
: SV served on the Advisory Board for Oncosec and received institutional funding for clinical trial research from Pfizer, Oncosec, and Seattle Genetics. MT reports research funding (to her institution) from AbbVie, AstraZeneca, Bayer, Biothera, Calithera, EMD Serono, Genentech, Merck, OncoSec Medical, Pfizer, PharmaMar, Tesaro and Vertex; an advisory role for AbbVie, Aduro, Blueprint Medicines, Celgene, Daiichi Sankyo, Genentech, Immunomedics, Lilly, Merck, Natera, OncoSec and Pfizer and DSMC membership for G1 Therapeutics and Immunomedics.